Predictors of antiviral treatment in Chronic Hepatitis -B (CHB) population.

BACKGROUND

CHB causes liver adversity and can be treated by antiviral drugs. HBV-DNA with Liver enzymes, HBeAg and, HBeAb plays a very crucial role in determining whether to provide treatment or not.

OBJECTIVE

This study aimed to derive the prognostic impact of HBeAb on CHB infection and the association between HB viral antigen, HB antibodies, and liver enzymes in providing antiviral treatment to CHB patients.

METHODS

This study was performed on all HBsAg-positive patients. A data extraction form was prepared to analyse biochemical measures associated with antiviral treatment.

RESULTS

An association between antiviral drugs and viral antigens was reported. The average age of participants was 36.89 (± 13.703), and separately, males were 37.64583 (±14.501), and females were 35.2093 (±11.708). Mean of ALT level 105.788 (±239.9647) and AST level 94.775 (± 234.0753). The highest HBeAg positivity was reported at the age of 15-30 years. 0.822 and 0.723p values were reported for the association between ALT, AST serum levels and HBeAg. HBeAg and antiviral therapy show a 0.022 significant value. Regression analysis reported HBeAg with different variables: age(p = 0.422),gender(p = 0.780), ALT(p = 0.819), and AST (p = 0.439).

CONCLUSION

Various biomarkers play an important role in treating HBsAg-positive patients. This study stated the pointers to be incorporated during the treatment of HBV patients.

ABBREVIATION: HBV, Hepatitis- B Virus; CHB, Chronic Hepatitis-B; HBsAg, Hepatitis-B surface Antigen; HBeAg, Hepatitis-B envelope antigen; HBeAb, Hepatitis-B envelope antibody.